NCT05438212
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Other, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 1-4 brain metastases, one of which requires resection (removal)
Exclusions: Patients with brain metastases NOT located more than 5 mm from the optic chiasm & brainstem; Patients with prior cranial radiotherapy, including whole brain radiotherapy, or SRS to the resection site (previous SRS to other lesions is allowed); Patients with evidence of leptomeningeal disease (LMD)
https://ClinicalTrials.gov/show/NCT05438212